利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.032 秒)

    Cycloalkyl hydroxyureas
    5.
    发明授权
    Cycloalkyl hydroxyureas 失效
    环烷基羟基脲

    公开(公告)号：US5681858A

    公开(公告)日：1997-10-28

    申请号：US525748

    申请日：1995-10-03

    申请人： Rodney William Stevens ,  Takashi Mano ,  Yoshiyuki Okumura ,  Masami Nakane

    发明人： Rodney William Stevens ,  Takashi Mano ,  Yoshiyuki Okumura ,  Masami Nakane

    IPC分类号： A61K31/17 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07C273/08 ,  C07C273/18 ,  C07C275/64 ,  C07C323/47 ,  C07C273/02 ,  C07C275/24

    CPC分类号： C07C275/64 ,  C07C323/47 ,  C07C2101/04 ,  C07C2101/08

    摘要： The present invention provides a novel N-hydroxyurea compound of chemical formula (I) wherein R.sup.1 and R.sup.2 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl; Ar is phenyl or mono-, di- or trisubstituted phenyl; A is a valence bond or a C.sub.1 -C.sub.6 alkylene chain, optionally having one double bond or one triple bond in the chain, and optionally having one or more C.sub.1 -C.sub.4 alkyl groups attached to the chain: X is oxygen or sulfur, n is an integer of 3 to 6; M is hydrogen, pharmaceutically acceptable cation or a metabolically cleavable group: and X and A may be attached at any available position on the ring. These compounds are useful for treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

    摘要翻译： PCT No.PCT / JP94 / 00567 Sec。 371 1995年10月3日第 102（e）日期1995年10月3日PCT 1994年4月5日PCT PCT。 第WO94 / 22814号公报 （I）本发明提供一种化学式（I）的新型N-羟基脲化合物，其中R 1和R 2各自独立地为氢或C 1 -C 4烷基; Ar是苯基或单，二或三取代的苯基; A是价键或C 1 -C 6亚烷基链，任选在链中具有一个双键或一个三键，并且任选地具有连接到链上的一个或多个C 1 -C 4烷基：X是氧或硫，n是 3〜6的整数; M是氢，药学上可接受的阳离子或代谢可切割基团：X和A可以连接在环上的任何可用位置。 这些化合物可用于治疗或缓解哺乳动物的炎性疾病，变态反应和心血管疾病，并用作用于治疗这些病症的药物组合物中的活性成分。

    Aryl or heteroaryl amide compounds
    6.
    发明授权
    Aryl or heteroaryl amide compounds 有权
    芳基或杂芳基酰胺化合物

    公开(公告)号：US07238714B2

    公开(公告)日：2007-07-03

    申请号：US10932463

    申请日：2004-09-02

    申请人： Kazunari Nakao ,  Seiji Nukui ,  Yoshiyuki Okumura ,  Tatsuya Yamagishi

    发明人： Kazunari Nakao ,  Seiji Nukui ,  Yoshiyuki Okumura ,  Tatsuya Yamagishi

    IPC分类号： C07D401/02 ,  A61K31/44

    CPC分类号： C07C233/87 ,  C04B35/632 ,  C07C235/60 ,  C07C255/57 ,  C07D213/643 ,  C07D213/65 ,  C07D213/82 ,  C07D257/04 ,  C07D401/12 ,  C07D417/12

    摘要： This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the like: R3 and R4 independently represent a hydrogen atom or the like: R5 represents —CO2H or the like: R6 represents an alkyl group having from 1 to 6 carbon atoms or the like: X represents a methylene group or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

    摘要翻译： 本发明提供式（I）的化合物：其中A表示苯基等：B表示芳基等：E表示1,4-亚苯基; R 1和R 2独立地表示氢原子等：R 3和R 4独立地表示氢原子， 氢原子等：R 5表示-CO 2 H等：R 6表示具有1至6个碳原子的烷基 原子等：X表示亚甲基等。 这些化合物可用于治疗由前列腺素介导的疾病状况，例如哺乳动物中的疼痛等。 本发明还提供了包含上述化合物的药物组合物。

    5-lipoxygenase inhibitors
    10.
    发明授权
    5-lipoxygenase inhibitors 失效
    5-脂氧合酶抑制剂

    公开(公告)号：US6063928A

    公开(公告)日：2000-05-16

    申请号：US207342

    申请日：1998-12-08

    申请人： Rodney W. Stevens ,  Takashi Mano ,  Kazunari Nakao ,  Yoshiyuki Okumura

    发明人： Rodney W. Stevens ,  Takashi Mano ,  Kazunari Nakao ,  Yoshiyuki Okumura

    IPC分类号： C07D233/60 ,  C07D233/61 ,  C07D309/08 ,  C07D521/00 ,  C07D207/323 ,  C07D207/36 ,  C07D235/10 ,  C07D235/14 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10

    CPC分类号： C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D309/08

    摘要： Novel compounds having the ability to inhibit 5-lipoxygenase enzyme and having the following formula I: ##STR1## and the pharmaceutically acceptable salts thereof, wherein Ar.sup.1 is a heterocyclic moiety which is selected from imidazolyl, pyrrolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, indolyl, indazolyl and benzimidazolyl, which is bonded to X.sup.1 through a ring nitrogen atom, and which may be optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C.sub.1-4 alkyl and the like; X.sup.1 is a direct bond or C.sub.1-4 alkylene; Ar.sup.2 is phenylene optionally substituted with halo, hydroxy, cyano, amino and the like; X.sup.2 is --A--X-- or --X--A-- wherein A is a direct bond or C.sub.1-4 alkylene and X is oxy, thio, sulfinyl or sulfonyl; Ar.sup.3 is phenylene, pyridylene, thienylene, furylene, oxazolylene or thiazolylene optionally substituted with one or two substituents selected from halo, hydroxy, cyano, amino, C.sub.1-4 alkyl and the like; R.sup.1 and R.sup.2 are each C.sub.1-4 alkyl, or together they form a group of formula --D.sup.1 --Z--D.sup.2 -- which together with the carbon atom to which it is attached defines a ring having 3 to 8 atoms, wherein D.sup.1 and D.sup.2 are C.sub.1-4 alkylene and Z is a direct bond or oxy, thio, sulfinyl, sulfonyl, or vinylene, and D.sup.1 and D.sup.2 may be substituted by C.sub.1-3 alkyl; and Y is CONR.sup.3 R.sup.4, CN, C(R.sup.3).dbd.N--OR.sup.4, COOR.sup.3, COR.sup.3 or CSNR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4 are each H or C.sub.1-4 alkyl. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

    摘要翻译： 具有抑制5-脂肪氧合酶并具有下式I的能力的新型化合物及其药学上可接受的盐，其中Ar1是选自咪唑基，吡咯基，吡唑基，1,2,3-三唑基， ，2,4-三唑基，吲哚基，吲唑基和苯并咪唑基，其通过环氮原子与X1连接，并且其可任选被一个或两个选自卤素，羟基，氰基，氨基，C 1-4烷基的取代基取代， 类似; X1是直接键或C1-4亚烷基; Ar 2是任选被卤素，羟基，氰基，氨基等取代的亚苯基; X2是-A-X或-X-A-，其中A是直接键或C 1-4亚烷基，X是氧基，硫代，亚磺酰基或磺酰基; Ar 3是任选被一个或两个选自卤素，羟基，氰基，氨基，C 1-4烷基等的取代基取代的亚苯基，亚吡啶基，亚噻吩基，呋喃基，恶唑基或噻唑基; R1和R2各自为C1-4烷基，或者它们一起形成式-D1-Z-D2-的基团，与其所连接的碳原子一起形成具有3至8个原子的环，其中D1和D2是 C 1-4亚烷基，Z是直接键或氧基，硫基，亚磺酰基，磺酰基或亚乙烯基，D1和D2可以被C 1-3烷基取代; 并且Y是CONR 3 R 4，CN，C（R 3）= N-OR 4，COOR 3，COR 3或CSNR 3 R 4，其中R 3和R 4各自为H或C 1-4烷基。 这些化合物可用于治疗或缓解哺乳动物的炎性疾病，变态反应和心血管疾病，并用作治疗这些病症的药物组合物中的活性成分。